12 Einträge gefunden

1. Assessment of imatinib as first-line treatment of chronic myeloid leukemia:10-year survival results of the randomized CML study IV and impact of non-CML determinants

   1. Hehlmann, R
   2. Lauseker, M
   3. Saußele, S
   4. Pfirrmann, M
   5. Krause, S
   6. Kolb, H J
   7. Neubauer, A

   2017 - Forschungsinformationssystem des UKE
2. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

   1. Miranda, M B
   2. Lauseker, M
   3. Kraus, M-P
   4. Proetel, U
   5. Hanfstein, B
   6. Fabarius, A
   7. Baerlocher, G M

   2016 - Forschungsinformationssystem des UKE
3. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.

   1. Goekkurt, E
   2. Hoehn, S
   3. Wolschke, Christine
   4. Wittmer, C
   5. Stueber, C
   6. Hossfeld, D K
   7. Stoehlmacher, J

   2006 - Forschungsinformationssystem des UKE
4. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo.

   1. Schuch, G
   2. Oliveira-Ferrer, Leticia
   3. Loges, Sonja
   4. Laack, E
   5. Bokemeyer, C
   6. Hossfeld, D K
   7. Fiedler, W

   2005 - Forschungsinformationssystem des UKE
5. Time benefit in the assessment of recurrences following fractionated radiotherapy in an experimental tumour system using positron-emission tomography with 18F-fluorodeoxyglucose.

   1. De Wit, M
   2. Raabe, A
   3. Seegers, B
   4. Buchert, Ralph
   5. Beck-Bornholdt, Hans-Peter
   6. Alberti, W
   7. Hossfeld, D K

   2004 - Forschungsinformationssystem des UKE
6. Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas.

   1. Murga-Penas, Eva-Maria
   2. Hinz, K
   3. Röser, K
   4. Copie-Bergman, C
   5. Wlodarska, I
   6. Marynen, P
   7. Hagemeijer, A

   2003 - Forschungsinformationssystem des UKE
7. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation.

   1. Weber, M
   2. Kröger, N
   3. Langer, F
   4. Hansen, A
   5. Zabelina, Tatjana
   6. Eifrig, B
   7. Hossfeld, D K

   2003 - Forschungsinformationssystem des UKE
8. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.

   1. Hegewisch-Becker, S
   2. Gruber, Y
   3. Corovic, A
   4. Pichlmeier, U
   5. Atanackovic, D
   6. Nierhaus, Axel
   7. Hossfeld, D K

   2002 - Forschungsinformationssystem des UKE
9. [New indications for thalidomide?]

   1. Tuinmann, Gert
   2. Hegewisch-Becker, S
   3. Hossfeld, D K

   2001 - Forschungsinformationssystem des UKE
10. Implantable device for intravenous drug delivery in the rat.

    1. de Wit, M
    2. Raabe, A
    3. Tuinmann, Gert
    4. Hossfeld, D K

    2001 - Forschungsinformationssystem des UKE
11. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

    1. de Wit, M
    2. Bohuslavizki, K H
    3. Buchert, Ralph
    4. Bumann, D
    5. Clausen, M
    6. Hossfeld, D K

    2001 - Forschungsinformationssystem des UKE
12. Chromosomal gains and losses are uncommon in hairy cell leukemia: a study based on comparative genomic hybridization and interphase fluorescence in situ hybridization.

    1. Dierlamm, J
    2. Stefanova, M
    3. Wlodarska, I
    4. Michaux, L
    5. Hinz, K
    6. Murga-Penas, Eva-Maria
    7. Maes, B

    2001 - Forschungsinformationssystem des UKE